Thursday, May 6, 2021 · 4:30pm ET
Download Investor Presentation
Evofem Biosciences, Inc. (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs).
The Company launched its first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in September 2020. Phexxi is the first and only hormone-free, prescription contraceptive vaginal gel. Learn more at phexxi.com.
The Company is evaluating its investigational drug candidate EVO100 (L-lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of urogenital transmission of chlamydia and gonorrhoea in women. Enrollment is underway in EVOGUARD, a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of these common STIs. Top-line results are expected in mid-2022.
EVOGUARD builds on positive, statistically significant results of a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE). This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo. The AMPREVENCE manuscript was published in the prestigious peer-reviewed journal American Journal of Obstetrics and Gynecology in 2021.